Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

LANGFORD, B.C. - Tobias Warschewski scored a highlight-reel goal in the 80th minute to give Cavalry FC a memorable 2-1 ...

The rapper has mastered the delicate balance between commercial success and politically charged music. How far will he push ...

Shares of Raymond James (NYSE:RJF – Get Free Report) have received an average rating of “Hold” from the twelve analysts that ...

Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Healthcare distributor and services company Cardinal Health (NYSE:CAH) beat Wall Street’s revenue expectations in Q4 CY2024, ...

Cardinal Health’s acquisition of Advanced Diabetes Supply Group hasn’t closed yet, but company officials said on a conference call to discuss second quarter financial results that ...